ALK(SZ:002940) Xin Lang Cai Jing·2025-09-15 07:11Core Viewpoint - On September 15, Angli康's stock price dropped by 5.02%, closing at 43.17 yuan per share, with a trading volume of 656 million yuan and a turnover rate of 8.04%, resulting in a total market capitalization of 8.709 billion yuan [1] Company Overview - Zhejiang Angli康 Pharmaceutical Co., Ltd. is located at 1000 North Shengzhou Avenue, Shengzhou City, Zhejiang Province, and was established on December 30, 2001, with its listing date on October 23, 2018 [1] - The company's main business involves the research, development, production, and sales of chemical raw materials and formulations [1] - The revenue composition of the main business is as follows: formulations 43.46%, raw materials 39.82%, specialty intermediates 12.44%, others 3.72%, and pharmaceutical excipients 0.56% [1] Shareholder Information - Among Angli康's top ten circulating shareholders, a fund under ICBC Credit Suisse Asset Management, namely ICBC Frontier Medical Stock A (001717), entered the top ten in the second quarter, holding 3.8022 million shares, accounting for 2.05% of circulating shares [2] - The estimated floating loss for this fund today is approximately 8.6691 million yuan [2] - ICBC Frontier Medical Stock A was established on February 3, 2016, with a latest scale of 9.33 billion yuan, and has achieved a return of 38.2% this year, ranking 934 out of 4223 in its category [2] - Over the past year, the fund has returned 48.29%, ranking 2139 out of 3803 in its category, and has achieved a cumulative return of 263.6% since inception [2] - The fund manager, Zhao Bei, has a tenure of 10 years and 305 days, with a total asset scale of 16.425 billion yuan [2]